Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
I think a lot of people are missing the blindingly obvious.........
WHEN the preCISION platform is proved and that proof is published either by RNS or in the scientific press it isn't maybe anymore - it is a proven massive step forward in Cancer treatment and patient welfare. Big Pharma companies won't care where it came from or who invented it or what the share price was or is. They will simply see the opportunity to both bank sensational profit and to help humanity in the ongoing fight against a modern curse.
I personally think one of the biggest issues will be that the competition authorities might involve themselves - particularly if it looks like the fastest way to peak uptake of the tech is being impeded.
I have personal experience of a regulatory body REQUIRING an asset be sold to a competitor basically of their choosing simply to ensure the most rapid development of a technology (our company potentially owned two assets - one through a takeover - both capable of making an impact in the same domain and to complete the merger one had to be divested to ensure both were developed at pace.
There is no way this doesn't change out of all recognition once the data are published and the question (many of us have already worked out for ourselves) is finally unambiguously answered.
Ophidian
Actually @PAH00 - as I pointed out some time back on Twitter AVA3996 will not displace current Velcade sales at all since Velcade is used in Blood Cancers so there is no FAP(a) expressing mass.
The big advantage is that Velcade is too toxic to be used in solid Tumours but with FAP targeting - it could be revolutionary in it's application. A whole NEW velcade market dwarfing the current use.
Ophidian
Over the last couple of days I tried to explain (on Twitter) how #AVCT AVA6000 P1a CT delivers a relatively much higher dose of doxorubicin to the TME than conventional therapy.
https://twitter.com/Ophidian18/status/1551884565060485121?s=20&t=wh_7b2Chv6w9vS3qmlQ-Og
How the targeted nature of that delivery significantly lessens the impact and potential of the usual chemo side effects.
https://twitter.com/Ophidian18/status/1552250479463305219?s=20&t=wh_7b2Chv6w9vS3qmlQ-Og
Back at the start of the CT, I laid out how #AVCT would follow the drug and metabolites through various sampling and testing
https://twitter.com/Ophidian18/status/1491083810322411523?s=20&t=wh_7b2Chv6w9vS3qmlQ-Og
(all of which has since been confirmed by the company in various communications) my contention being that #AVCT ALREADY have the data to confirm precision is working in humans just as in the preclinical rodent models.
So what remains to be known ? One thing and one thing only, confirmation through biopsies of the concentration of doxorubicin in the TME. Whilst this can be inferred from data gathered along the way it can only be definitively confirmed through biopsy which brings us back to the Tweet I posted ahead of this series –
https://twitter.com/Ophidian18/status/1551484677281677312?s=20&t=wh_7b2Chv6w9vS3qmlQ-Og
the confirmation from Alastair Smith at the AGM. In my view #AVCT ALREADY have the first biopsy data in their possession, THEY KNOW and everything we see in their behaviour supports that assertion. Patience is all that is needed now.
Ophidian
it's an interesting hypothesis CO but to be honest I think research is heading in different directions nowadays. Targeting something that can directly target DNA in cancer cells for example might be easily guided in by preCISION perhaps. There are many potential ways to maximise and exploit this breakthrough to the benefit of patients in my view. Your suggestion is quite feasible however.
Ophidian
just for clarity CO- it's not the half life of dox in the body - it's the initial distribution half life or how long it stays in the blood without entering tissue. The half life in the body is about 33 hours but by then it's in tissues and doing harm.
Ophidian
@SeethreeIPO - I think you're bang on. It was an attempt to undermine me and to obfuscate the extremely good news for investors around Biopsies.
For the record - Dr Smith could see the recording device as it was less than 3 metres in front of him in plain view unobscured by anyone placed on the front row. He like most intelligent people would know that it is neither illegal, nor unexpected to record the proceedings in a public place (no consent required btw). There were multiple recording being made on the day apparently.
Now having managed to get yesterdays somewhat more useful thread containing this removed and thereby losing some good research from RAH - I expect this one to go pdq now as well.
Anyone who want to be involved in grown up meaningful debate try Twitter
Ophidian
" producing that ridiculous LFT timetable of yours" dear boy - it was an annunciation of the steps involved not a time forecast as most sensible observers could understand having been originally posted with no timings at all. It was later validated by the company producing the almost identical set of steps in the same order - but best you reinforce the Ad hominem strategy the team of bashers fell in to.
Isn't this AS bashing and LFD hangover getting a bit old now ? Personally I'm delighted that the company chose to cut it's teeth on something like the LFD rather than on AVA6000. Critical mass is perhaps the biggest single determinant in small Biotech success or failure and with the LFD AS secured enough money to put a team in place that means AVA6000 can succeed plus all the great lessons learned along the way.
A common trait of many great leaders, innovators, and entrepreneurs is a risk mindset. They understand that risk and reward are fundamentally linked, and that failure is paradoxically an integral part of success. Robert F. Kennedy described this well: “Only those who dare to fail greatly can ever achieve greatly.”
In Jeff Bezos’s 1997 letter to shareholders, he said: “Nine times out of ten, you’re going to fail. But every once in a while, you’ll hit a home run that in business terms is more like one thousand runs. Given a ten percent chance of a one hundred times payoff, you should take that bet every time.”
Bill Gates said in his book, Business @ the Speed of Thought, that “once you embrace unpleasant news not as negative but as evidence of a need for change, you aren’t defeated by it. You’re learning from it. It’s all in how you approach failures. And believe me, we know a lot about failures at Microsoft.”
elements taken from: https://www.forbes.com/sites/chuckswoboda/2020/08/24/what-jeff-bezos-and-bill-gates-learned-about-failure-that-made-them-successful/
Ophidian
As I Tweeted yesterday - MyHealthChecked just announced 5 DNA cheek swab "wellness tests" for Intolerances & Sensitivities, Weight Management, Heart Profile, Vitamins & Minerals and Glucose Management. retailing at £54 a pop - there is a lot of profit in an LFD test (probably much more accurate and quicker) with a £54 price tag.
Ophidian
https://avacta.com/wp-content/uploads/2022/06/AGM-Update-2022_.pdf
slide 14